A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease



Status:Recruiting
Conditions:Gastrointestinal, Gastrointestinal, Diabetes, Diabetes
Therapuetic Areas:Endocrinology, Gastroenterology
Healthy:No
Age Range:18 - 75
Updated:3/30/2019
Start Date:March 5, 2017
End Date:June 7, 2019
Contact:Reference Study ID Number: GC39547 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending−dose study of
the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A
in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic
fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled
across multiple sites in the United States. Participants will be randomly assigned to receive
study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to
8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to
clinic for an optional pre-screening visit.


Inclusion Criteria:

For T2DM Cohort only:

- Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2.

- A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening

- Current stable treatment (at least 3 months) for diabetes

- Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.

- For women of childbearing potential, agreement to remain abstinent or use reliable
contraception during treatment period and for at least 42 days after last dose of
study drug

- For men, agreement to remain abstinent or use reliable contraception and agree to
refrain from donating sperm

- For NAFLD cohort only:

- BMI ≥ 25 kg/m2 and ≤ 40 kg/m2

- At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using
variables from the NAFLD liver fat score

- Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton
density fat fraction [PDFF]) prior to randomization.

Exclusion Criteria:

- Pregnant, lactating, or intending to become pregnant within 42 days after the last
dose of study drug is administered

- Suspected or confirmed diagnosis of Type 1 diabetes

- Significant cardiac disease

- Any psychiatric illness that increases the risk of participation in the study

- History of severe allergic, anaphylactic, or other hypersensitivity reactions, or
severe systemic bacterial, fungal, or parasitic infections

- Poor peripheral venous access

- Received blood products within 2 months before dosing

- Donation or loss of blood within 30-56 days prior to study drug administration

- Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or
human immunodeficiency virus (HIV) antibody

- Liver enzymes greater than acceptable limits

- History of eating disorders or surgical procedures for weight loss

- Active participation in a structured weight loss or dietary program

- Treatment with investigational therapy or exposure to any biological therapy

- Illicit drug use, marijuana use, or alcohol abuse

- Current use of more than one pack of cigarettes a day or equivalent nicotine-
containing products

- Any serious medical condition or abnormality in clinical laboratory tests
We found this trial at
23
sites
5160 Boulevard Décarie
Montreal, Quebec H3X 2H9
?
mi
from
Montreal,
Click here to add this to my saved trials
911 E. Hallandale Beach Blvd
Hallandale Beach, Florida 33009
954-455-5757
?
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
321 East 10th Street
Anniston, Alabama 36207
?
mi
from
Anniston, AL
Click here to add this to my saved trials
321 East 10th Street
Anniston, Alabama 36207
?
mi
from
Anniston, AL
Click here to add this to my saved trials
Arlington, Texas 76012
?
mi
from
Arlington, TX
Click here to add this to my saved trials
750 Hammond Drive Northeast
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Berlin, New Jersey
?
mi
from
Berlin, NJ
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Coronado, California 92118
?
mi
from
Coronado, CA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
High Point, North Carolina 27265
?
mi
from
High Point, NC
Click here to add this to my saved trials
Knoxville, Tennessee 37920
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Los Angeles, California 90057
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33165
?
mi
from
Miami, FL
Click here to add this to my saved trials
5721 West 119th Street
Overland Park, Kansas 66209
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Rialto, California 92377
?
mi
from
Rialto, CA
Click here to add this to my saved trials
Sacramento, California
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Shavano Park, Texas 78231
?
mi
from
Shavano Park, TX
Click here to add this to my saved trials
113 East Grover Street
Shelby, North Carolina 28150
?
mi
from
Shelby, NC
Click here to add this to my saved trials
Stanford, California 94304
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Tustin, California 92780
?
mi
from
Tustin, CA
Click here to add this to my saved trials